VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Other Events
Item 8.01 Other Events.
On February 13, 2019, VistaGen Therapeutics, Inc. (the “Company”) announced that the U.S. Patent and Trademark Office provided a Notice of Allowance for a patent related to methods of treating depression with PH10, the Company’s investigational new generation CNS nasal spray in Phase 2 development for major depressive disorder (“MDD”). A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1. On February 19, 2019, the Company announced that the Japan Patent Office issued to the Company a patent related to methods of treating depression with AV-101, the Company’s oral NMDA receptor glycine site antagonist in Phase 2 development for treatment of MDD. The patent also relates to methods of treating hyperalgesia, which is extreme sensitivity to pain. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits.
See Exhibit Index.
VistaGen Therapeutics, Inc. Exhibit
EX-99 2 ex99-02192019_010226.htm Secconnect.com Exhibit 99.1 VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10 SOUTH SAN FRANCISCO,…
To view the full exhibit click here
About VistaGen Therapeutics, Inc. (NASDAQ:VTGN)
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
